Sign In
Buy STOK
$28.86
-1.18 (-3.93%)
At Close: Jul 31, 2026
Stoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico; Biogen receives exclusive rest of world commercialization rights Collaboration broadens Biogen's rare disease
Stoke Therapeutics: A Pivotal Moment For This RNA Pioneer
02:23pm, Sunday, 16'th Feb 2025
Stoke Therapeutics' RNA-based treatments for severe neurological and ophthalmic disorders, particularly zorevunersen for Dravet syndrome, show potential for long-term value beyond a single drug. Finan
Strength Seen in Stoke Therapeutics (STOK): Can Its 9.4% Jump Turn into More Strength?
09:56am, Wednesday, 05'th Feb 2025
Stoke Therapeutics (STOK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near te
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?
11:31am, Friday, 17'th Jan 2025
Here, we discuss some reasons why investing in STOK now may turn out to be a prudent move.
Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
04:30pm, Wednesday, 08'th Jan 2025
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today
4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow
12:51pm, Tuesday, 24'th Dec 2024
Here, we discuss four biotech stocks, ADMA, TARS, STOK and CDXC, which have returned more than 50% year to date and have room for more growth in 2025.
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today
STOK Shares Up on FDA's Breakthrough Tag for Dravet Syndrome Drug
11:15am, Thursday, 05'th Dec 2024
The FDA bestows a Breakthrough Therapy designation to Stoke Therapeutics' zorevunersen for the treatment of Dravet syndrome. Stock rises.
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today
Stoke Therapeutics (STOK) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
10:55am, Wednesday, 20'th Nov 2024
Stoke Therapeutics (STOK) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement a
Wall Street Analysts Believe Stoke Therapeutics (STOK) Could Rally 66.84%: Here's is How to Trade
10:55am, Friday, 08'th Nov 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 66.8% in Stoke Therapeutics (STOK). While the effectiveness of this highly sought-after metric is questionable,
Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates
09:16am, Tuesday, 05'th Nov 2024
Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.55 per share a year ago.
Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
11:06am, Tuesday, 29'th Oct 2024
Stoke Therapeutics (STOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
